Latest News
Monday August 11, 2008 — Zacks.com: Analyst Blog
In the second quarter of 2008, revenue for Alnylam Pharmaceuticals, Inc. (ALNY) came in at $23.8 million, an 161% increase year-over-year, but less than our estimate of $33 million. The significant increase in revenues in the second quarter of 2008 was primarily related to $13.4 million o...
Tuesday July 22, 2008 — Zacks.com: Analyst Blog
Alnylam Pharmaceuticals Inc. (ALNY) develops novel therapeutics based on RNA interference, or RNAi technology. The company has continued the deal-signing spree with a development and commercialization deal with GlaxoSmithKlinePlc. (for Regulus Therapeutics), Alnylam's joint venture with I...
Saturday May 31, 2008 — Zacks.com: Analyst Blog
Alnylam Pharmaceuticals (ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi technology. After signing a multi-million dollar deal with Roche in 2007, the company has continued the deal-signing spree with a development and commercializatio...
Tuesday May 27, 2008 — Isis Pharmaceuticals, Inc.
CARLSBAD, Calif., May 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. as its portion of the upfront fees in the recently announced transaction between Takeda Pharmaceutical Company Limited and A...
Tuesday April 1, 2008 — Zacks.com: Analyst Blog
Alnylam Pharmaceuticals (ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi technology. 2007 was an exciting and a transformative year for the company. The multimillion dollar deal with Roche changed the financial landscape of the company...
Friday March 7, 2008 — QED International Associates
NEW YORK, March 6 /PRNewswire/ -- QED International Associates, Inc, administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on March 11, 2008, Alnylam Pharmaceutical...
Thursday February 14, 2008 — Zacks.com: Analyst Blog
Alnylam Pharmaceuticals (ALNY), is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi technology. The year 2007 was an exciting and a transformative one for the company. The multimillion dollar deal with Roche changed its financial landscape and e...
Tuesday February 12, 2008 — WallStreet Direct, Inc.
NEW YORK, Feb. 12 /PRNewswire/ -- The Analyst's Review is a daily podcast hosted by WallSt.net editor, Henry Truc that airs every morning at 9 a.m. EST on http://radio.wallst.net/profile.asp?id=193.The show features informative interviews with Wall Street analysts on a wide range of topics includ...
Friday December 28, 2007 — Zacks.com: Analyst Blog
An update has just come out today on Alnylam Pharmaceuticals (ALNY), in which senior bioscience analyst Grant Zeng, CFA suggests a Hold rating on the company. Here we find out why:'Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interferen...
Wednesday September 26, 2007 — Zacks.com: Analyst Blog
A Hold recommendation has recently been issued to pharmaceutical company Alnylam Pharmaceuticals, Inc. (ALNY) by Zacks senior pharmaceutical industry analysts Grant Zeng, CFA and Varun Parwal. Here's what their latest update had to say:'Alnylam Pharmaceuticals is a biopharmaceutical compa...